Clinical Trial Update: Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating de-escalated adjuvant radiation with adjuvant nivolumab in intermediate-high risk HPV-positive oropharyngeal squamous cell carcinoma ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Robert L. Ferris, MD, PhD | Conditions: Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-01-13